Aequus Pharmaceuticals Inc. Stock

Equities

AQS

CA0076361033

Pharmaceuticals

Delayed Toronto S.E. 03:56:17 2024-05-13 pm EDT 5-day change 1st Jan Change
0.025 CAD +25.00% Intraday chart for Aequus Pharmaceuticals Inc. +66.67% 0.00%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Sales 2022 1.38M 1.01M Sales 2023 255K 187K Capitalization 3.32M 2.43M
Net income 2022 -3M -2.2M Net income 2023 -2M -1.47M EV / Sales 2022 5.17 x
Net Debt 2022 2.49M 1.82M Net Debt 2023 4.85M 3.56M EV / Sales 2023 32 x
P/E ratio 2022
-1.45 x
P/E ratio 2023
-1.12 x
Employees 12
Yield 2022 *
-
Yield 2023
-
Free-Float 85.32%
More Fundamentals * Assessed data
Dynamic Chart
Aequus Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Aequus Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Aequus Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Aequus Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Aequus Says Zimed PF Now Available in Canada MT
Aequus Pharmaceuticals Inc. Announces Launch of Zimed PF in Canada CI
Aequus Pharmaceuticals Announces Zimed PF Website Launch MT
Aequus Pharmaceuticals Pauses Sales Of Evolve Intensive Eyedrops, Gel in Canada MT
Aequus Pharmaceuticals Inc. Announces Pause in Sales of Evolve Intensive Eyedrop and Intensive Gel Products in Canada CI
Aequus Pharmaceuticals Announcds Financing to Support Launch of Zimed Preservative Free MT
Aequus Pharmaceuticals Inc. Increases Its Debt by $400,000 to Support the Launch of Zimed Pf CI
Aequus Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Aequus Pharmaceuticals Inc. Auditor Raises 'Going Concern' Doubt CI
Aequus Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Aequus Pharmaceuticals Inc. Announces the Resignation of Stuart Fowler from the Board of Directors CI
More news
1 day+25.00%
1 week+66.67%
Current month+66.67%
1 month+66.67%
3 months+25.00%
6 months-44.44%
More quotes
1 week
0.02
Extreme 0.015
0.03
1 month
0.01
Extreme 0.01
0.03
Current year
0.01
Extreme 0.01
0.03
1 year
0.01
Extreme 0.01
0.06
3 years
0.01
Extreme 0.01
0.16
5 years
0.00
Extreme 0
0.29
10 years
0.00
Extreme 0
0.79
More quotes
Managers TitleAgeSince
Founder - 12-12-31
Chief Executive Officer 56 13-01-02
Director of Finance/CFO 55 16-07-21
Members of the board TitleAgeSince
Chief Executive Officer 56 13-01-02
Director/Board Member 51 21-02-14
Director/Board Member 54 14-12-17
More insiders
Date Price Change Volume
24-05-13 0.025 +25.00% 543,000
24-05-10 0.02 0.00% 246,000
24-05-09 0.02 +33.33% 2,943,500
24-05-08 0.015 0.00% 110,000
24-05-07 0.015 0.00% 6,000

Delayed Quote Toronto S.E., May 13, 2024 at 03:56 pm EDT

More quotes
Aequus Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company focused on developing, advancing, and promoting differentiated products. The Company is engaged in the sale and marketing of several commercial products in ophthalmology and transplant. Its pipeline products include Evolve Intensive Gel, Evolve Daily Intensive, SCOPE Portfolio, Zimed PF and REV-0100 / ReVision. Evolve Intensive Gel and Evolve Daily Intensive contains lubricating eye drops intended for use in the relief of discomfort that arises from dry eye sensations, including dryness, soreness, feelings of grit, and irritation. Zimed PF is a preservative-free multi-dose Bimatoprost for glaucoma patients in Canada. REV-0100 is in preclinical development as a treatment for Stargardt disease. It plans to build on its Canadian commercial platform through the launch of additional products that are either created internally or brought in through an acquisition or license.
More about the company
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW